Tolera Therapeutics Overview

  • Year Founded
  • 2007

Year Founded

  • Status
  • Out of Business

  • Latest Deal Type
  • Out of Business

Tolera Therapeutics General Information

Description

Developer of immune modulation transplant therapies created to address unmet medical needs with safer, targeted solutions. The company's immune modulation transplant therapies target the human alpha-beta T-cell receptor that appears to render pathologic T-cells inert and through a unique signaling pathway that expands regulatory T-cells in a novel, non-depleting manner, enabling the lives of patients suffering from a broad spectrum of autoimmune and immune-meditated diseases to improve.

Contact Information

Website
www.tolera.com
Ownership Status
Out of Business
Financing Status
Formerly VC-backed
Corporate Office
  • P.O. Box 970
  • Portage, MI 49081
  • United States
+1 (269)
Primary Industry
Pharmaceuticals
Vertical(s)
Corporate Office
  • P.O. Box 970
  • Portage, MI 49081
  • United States
+1 (269)

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Tolera Therapeutics Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
8. Out of Business 01-Feb-2017 Completed Out of Business
7. Later Stage VC 17-Sep-2014 Completed Generating Revenue
6. Angel (individual) 13-Sep-2013 Completed Generating Revenue
5. Later Stage VC (Series B3) 16-Oct-2012 Completed Generating Revenue
4. Angel (individual) 01-Dec-2011 Completed Startup
3. Early Stage VC (Series B) 07-Jun-2010 Completed Startup
2. Early Stage VC (Series A) 16-Jun-2008 $7.84M $7.84M Completed Startup
1. Accelerator/Incubator Completed Startup
To view Tolera Therapeutics’s complete valuation and funding history, request access »

Tolera Therapeutics Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate ($) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Series B3
Series B2
Series B1 17,313,277 $0.001000 $0.06 $0.72 $0.72 1x $0.72 40.41%
Series A 11,872,094 $0.001000 $0.05 $0.66 $0.66 1x $0.66 27.71%
To view Tolera Therapeutics’s complete cap table history, request access »

Tolera Therapeutics Patents

Tolera Therapeutics Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
AU-2012332193-A1 Antibody and methods for selective inhibition of t-cell responses Inactive 03-Nov-2011
CA-2853687-A1 Antibody and methods for selective inhibition of t-cell responses Inactive 03-Nov-2011
EP-2773670-A2 Antibody and methods for selective inhibition of t-cell responses Inactive 03-Nov-2011
EP-2773670-A4 Antibody and methods for selective inhibition of t-cell responses Inactive 03-Nov-2011
WO-2013067517-A2 Antibody and methods for selective inhibition of t-cell responses Inactive 03-Nov-2011 C07K16/2803
To view Tolera Therapeutics’s complete patent history, request access »

Tolera Therapeutics FAQs

  • When was Tolera Therapeutics founded?

    Tolera Therapeutics was founded in 2007.

  • Where is Tolera Therapeutics headquartered?

    Tolera Therapeutics is headquartered in Portage, MI.

  • What industry is Tolera Therapeutics in?

    Tolera Therapeutics’s primary industry is Pharmaceuticals.

  • Is Tolera Therapeutics a private or public company?

    Tolera Therapeutics is a Private company.

  • What is Tolera Therapeutics’s current revenue?

    The current revenue for Tolera Therapeutics is .

  • How much funding has Tolera Therapeutics raised over time?

    Tolera Therapeutics has raised $19.4M.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process